Ets-1: a new player in the pathogenesis of systemic lupus erythematosus?

v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) (Ets-1) is a member of the Ets family of transcription factors that share a unique Ets DNA binding domain. They control a wide variety of cellular processes including cell proliferation and differentiation. Recently, two genome-wide association studies in systemic lupus erythematosus (SLE) independently identified genetic variants in Ets-1 associated with SLE. Interestingly, previous studies have found that Ets-1-deficient mice develop lupus-like disease characterized by high titers of IgM and IgG autoantibodies, immune complex-mediated glomerulonephritis, and local activation of complement. In addition, Ets-1 is also involved in many cellular abnormalities that are known to participate in SLE pathogenesis, such as its role in negative regulation of Th17 cell and B cell differentiation. All these findings suggest that Ets-1 may play an important role in the pathogenesis of SLE. This article will focus on current understanding of the role of Ets-1 in the physiological and pathological functions associated with SLE. It is the intention of the article to provide insights which may assist in the development of Ets-1 based approaches for the treatment of SLE.

[1]  Liangdan Sun,et al.  TNIP1, SLC15A4, ETS1, RasGRP3 and IKZF1 are associated with clinical features of systemic lupus erythematosus in a Chinese Han population , 2010, Lupus.

[2]  P. Sham,et al.  Genome-Wide Association Study in Asian Populations Identifies Variants in ETS1 and WDFY4 Associated with Systemic Lupus Erythematosus , 2010, PLoS genetics.

[3]  Ying Wang,et al.  Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus , 2009, Nature Genetics.

[4]  L. Garrett-Sinha,et al.  Ets-1 Regulates Plasma Cell Differentiation by Interfering with the Activity of the Transcription Factor Blimp-1* , 2008, Journal of Biological Chemistry.

[5]  E. Bettelli,et al.  Ets-1 is a negative regulator of Th17 differentiation , 2007, The Journal of experimental medicine.

[6]  R. D. Hatton,et al.  IL-17 family cytokines and the expanding diversity of effector T cell lineages. , 2007, Annual review of immunology.

[7]  L. Garrett-Sinha,et al.  Ets-1 deficiency leads to altered B cell differentiation, hyperresponsiveness to TLR9 and autoimmune disease. , 2005, International immunology.

[8]  I. Ho,et al.  Ets-1, a functional cofactor of T-bet, is essential for Th1 inflammatory responses , 2005, The Journal of experimental medicine.

[9]  P. Lipsky,et al.  B cell abnormalities in systemic lupus erythematosus , 2003, Arthritis research & therapy.

[10]  Jürgen Dittmer,et al.  Molecular Cancer BioMed Central Review The Biology of the Ets1 Proto-Oncogene , 2003 .

[11]  Karin Reiter,et al.  Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. , 2003, Arthritis and rheumatism.

[12]  J. Hagman,et al.  Activation of the Early B-Cell-Specific mb-1 (Ig-α) Gene by Pax-5 Is Dependent on an Unmethylated Ets Binding Site , 2003, Molecular and Cellular Biology.

[13]  T. Grundström,et al.  Calcium regulation of GM-CSF by calmodulin-dependent kinase II phosphorylation of Ets1. , 2002, Molecular biology of the cell.

[14]  C. Garvie,et al.  Structural Analysis of the Autoinhibition of Ets-1 and Its Role in Protein Partnerships* , 2002, The Journal of Biological Chemistry.

[15]  C. Garvie,et al.  Structural studies of Ets-1/Pax5 complex formation on DNA. , 2001, Molecular cell.

[16]  F. Powrie,et al.  Control of experimental inflammatory bowel disease by regulatory T cells. , 2000, American journal of respiratory and critical care medicine.

[17]  L. Glimcher,et al.  Lineage commitment in the immune system: the T helper lymphocyte grows up. , 2000, Genes & development.

[18]  M. Petri,et al.  3′ polymorphisms of ETS1 are associated with different clinical phenotypes in SLE , 2000, Human mutation.

[19]  A. Nordheim,et al.  Regulation of the Human Interleukin-5 Promoter by Ets Transcription Factors , 1999, The Journal of Biological Chemistry.

[20]  N Muthusamy,et al.  The Ets-1 transcription factor is required for the development of natural killer cells in mice. , 1998, Immunity.

[21]  M. F. Shannon,et al.  ETS1, NFκB and AP1 synergistically transactivate the human GM – CSF promoter , 1997, Oncogene.

[22]  F. Alt,et al.  Increased T-cell apoptosis and terminal B-cell differentiation induced by inactivation of the Ets-1 proto-oncogene , 1995, Nature.

[23]  N. Muthusamy,et al.  Defective activation and survival of T cells lacking the Ets-1 transcription factor , 1995, Nature.

[24]  N. Bhat,et al.  Role of ETS1 in IL-2 gene expression. , 1995, Journal of immunology.

[25]  R. Fisher,et al.  ets-1 in astrocytes: expression and transmitter-evoked phosphorylation , 1995, Molecular and cellular biology.

[26]  R. de Waal Malefyt,et al.  Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. , 1993, Journal of immunology.

[27]  N. Bhat,et al.  Reciprocal expression of human ETS1 and ETS2 genes during T-cell activation: regulatory role for the protooncogene ETS1. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[28]  L. Pasquier,et al.  Orphanet Journal of Rare Diseases BioMed Central Review , 2006 .

[29]  M. Pufall,et al.  Ets-1 flips for new partner Pax-5. , 2002, Structure.

[30]  G. Prete.  The concept of type-1 and type-2 helper T cells and their cytokines in humans. , 1998 .

[31]  M. F. Shannon,et al.  ETS1, NFkappaB and AP1 synergistically transactivate the human GM-CSF promoter. , 1997, Oncogene.

[32]  R. Coffman,et al.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. , 1989, Annual review of immunology.